EPICENTRX PUBLICATIONS

Recent Publications and Conference Presentations

Presentation & Abstract
Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Kim M, Parmar H, Aryal M, Schipper M, Devasia T, Kesari S, Morikawa A, et al.
Society for NeuroOncology (SNO) 23rd Annual Meeting, Nov 15th-18th 2018, New Orleans, LA

 

Case Report
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets
Ojemuyiwa M, Zeman K, Spira A, Oronsky B, Ray C, Trepel, JB, Lee MJ, Onyiuke I, Brzezniak C
Clinical Case Reports, In Press. 2018

Presentation & Abstract
RRx-001 is a phase 3-ready small molecule which immunonormalizes the tumor microenvironment
Cabrales P, Carter C, Oronsky B, Reid T
Society for Immunotherapy of Cancer (SITC) Annual Meeting, Nov 7-11 2018, Washington DC

Presentation & Abstract
BETATRAP, a replication competent type 5 adenovirus carrying a TGF-beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
Larson C, Reid T, Carter C, Oronsky B
Society for Immunotherapy of Cancer (SITC) Annual Meeting, Nov 7-11 2018, Washington DC

Presentation & Abstract
Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Kim M.
60th ASTRO Annual Meeting – American Society for Radiation Oncology (ASTRO), Oct 22nd 2018, San Antonio, TX

Review
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)
Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter C, Reid T.
OncoImmunology, 2018, Jul 23.

Data Paper
Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001
Oronsky B, Oronsky N, Cabrales P.
J Cell Mol Med. 2018 Jul 16. doi: 10.1111/jcmm.13791.

Case Report
Abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer
Oronsky B, Larson C, Reid T, Carter C.
Journal of Investigative Medicine High Impact Case Reports, July 6, 2018.

Data Paper
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
Oronsky B, Reid T, Oronsky A , Caroen S, Carter C, Cabrales P.
Oncotarget. 2018 Apr 5.

Review
A review of clinical radioprotection and chemoprotection for oral mucositis
Oronsky B, Burbano E, Kim M, Oronsky N, Lybeck M, Goyal S, Cabrales P, Caroen S, Oronsky A, Carter C.
Translational Oncology. Apr 2018.

Case Report
A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet
Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E.
J Investig Med High Impact Case Rep. 2018 Mar 7.

Data Paper
A note on improved statistical approaches to account for pseudoprogression
Abrouk N, Oronsky B, Caroen S, Ning S, Knox S, Peehl D.
Cancer Chemother Pharmacol. 2018 March, 81(3): 621-626.

Presentation & Abstract
Sensitization of neuroendocrine prostate cancer by RRx-001
Peehl D, Zhao H, Shoucheng N.
2018 Genitourinary Cancers Symposium; February 8, 2018.

Case Report
A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
Brzezniak C, Oronsky B, Aggarwal R.
Eur Urol. 2018 Feb;73(2):306-307. doi: 10.1016/j.eururo.2017.09.010. Epub 2017 Sep 21.

Presentation & Abstract
Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model
Kimberly J. Jurgensen, Lynnette H. Cary, Thomas A. Summers, Corey A. Carter, William K. J. Skinner
2017 Radiation Research Society Annual Meeting, Cancun, MX

Review
Nothing but NET: A review of neuroendocrine tumors and carcinomas.
Oronsky B, Ma P, Morgensztern D, Carter C.
Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5.

Review
Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management.
Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M, Reid T, Carter C.
Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20.

Review
What’s new in SCLC? A review.
Oronsky B, Reid T, Oronsky A, Carter C.
Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6.

Review
Nitric oxide donor-based cancer therapy: advances and prospects
Huang Z, Fu J, Zhang Y.
J Med Chem. 2017 Sep 28 doi: 10.1021/acs.jmedchem.6b01672.

Review
No patient left behind: The promise of immune priming with epigenetic agents.
Carter C, Oronsky B, Roswarski J, Oronsky A, Oronsky N, Scicinski J, Lybeck H, Kim M, Lybeck M, Reid T.
Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017.

Data Paper
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Raghunand N, Scicinski J, Guntle G, Jagadish B, Mash E, Bruckheimer E, Oronsky B, Korn R.
Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.

Data Paper
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.
Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B.
Expert Rev Hematol. 2017 Jun;10(6):575-582. doi: 10.1080/17474086.2017.1324779. Epub 2017 May 22.

Review
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray C, Spira A, Trepel JB, Carter C, Cottrill H.
Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25.

Presentation & Abstract
The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox S, Peehl D.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC.

Presentation & Abstract
Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis
Jha S, Summers T, Zeman K, Brzezniak C, Carter C, Ferry L, Scicinski J, Oronsky B, Caroen S, Trepel J, Cabrales P, Day R.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC.

Presentation & Abstract
Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal cancer cell lines
Rory Kokelaar R, Jones H, Beynon J, Harris D, Jenkins G.
AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC.

Case Report
RRx-001 priming of PD-1 inhibition in the treatment of small cell carcinoma of the vagina: A rare gynecological tumor.
Brzezniak C, Oronsky B, Trepel J, Summers T Jr, Cabrales P, Lee M, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck H, Brown J, Reid T, Carter C.
Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

Data Paper
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl D.
Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

Review
RRx-001: A systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox S, Peehl D, Zhao H, Ning S, Cabrales P, Summers T Jr, Reid T, Fitch W, Kim M, Trepel J, Lee M, Kesari S, Abrouk N, Day R, Oronsky A, Ray C, Carter C.
Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600.

Presentation & Abstract
QUADRUPLE THREAT: A pilot phase 2 study of RRx-001 in advanced lung cancer prior to re-administration of platinum doublets
Brzezniak C, Quinn M, Zeman K, Oronsky B, Scicinski J, Caroen S, Abrouk N, Degesys A, Schmitz B, Peterson P, Roswarski J, Trepel J, Lee M, Lee S, Tomita Y, Day R, Jha S, Carter C.
Journal of Thoracic Oncology January 2017 Volume 12, Issue 1, Supplement, Pages S1090–S1091.